BeiGene files patent suits against San­doz, MSN Group

BeiGene cel­e­brat­ed its fifth in­di­ca­tion for Brukin­sa with a law­suit.

A day af­ter win­ning an ac­cel­er­at­ed ap­proval in fol­lic­u­lar lym­phoma, BeiGene filed com­plaints against San­doz and sub­sidiaries of MSN Group over ap­pli­ca­tions to mar­ket gener­ic ver­sions of Brukin­sa. The com­pa­ny claims that San­doz and MSN in­fringed patents on the blood can­cer block­buster and has asked the court to bar San­doz and MSN from com­mer­cial­iz­ing their gener­ics un­til the patents ex­pire.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.